Artiva Biotherapeutics, Inc. ARTV

About Artiva Biotherapeutics, Inc. (ARTV): stock profile, AI score and financials

Artiva Biotherapeutics, Inc. (ARTV) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ARTV at 9.7/100 on a composite quality score built from its SEC filings, placing it at rank #2,711 of 2,748 stocks — the bottom half of the AI-ranked universe. Areas of concern include free cash flow (0.2) and profitability (0.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 0.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Artiva Biotherapeutics, Inc. reports net income of $-25.0M, free cash flow of $-20.8M. Top institutional holders of ARTV by reported 13-F value include RA CAPITAL MANAGEMENT, L.P., VIKING GLOBAL INVESTORS, Blackstone, based on the most recent SEC filings. ARTV trades on the Nasdaq exchange and files with the SEC under CIK 1817241. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ARTV daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Artiva Biotherapeutics, Inc. directly from SEC EDGAR.

Financials through the period ended Jun 30, 2026SEC EDGAR: CIK 1817241 →